- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000138
FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis
December 13, 2023 updated by: Gad Abikhzer, Jewish General Hospital
Giant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment.
Although older technology non-digital PET/CT scans are routinely used for the diagnosis of GCA in large arteries, they have not been able to reliably detect inflammation of the small arteries responsible for blindness.
Recent technological advances have enabled PET/CT imaging of millimetric disease in the body, which are now able to resolve small arteries.
In the proposed research study, patients who are suspected by their doctors to have GCA will undergo an ultrasound of the temporal arteries, and digital PET/CT scan after injection of radioactive glucose.
Digital PET/CT scans will be interpreted for the presence of abnormal uptake in the large and small arteries, as well as for the presence of other causes of the patient's symptoms.
The diagnostic accuracy of PET/CT and ultrasound will be evaluated with respect to an expert panel diagnosis of giant cell arteritis and compared.
Results will be adjusted for lack of a perfect reference test using advanced statistics.
The goal will be to see if digital PET/CT can become a single, integrated test to diagnose this disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
134
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gad Abikhzer, MD
- Phone Number: 514-340-8222
- Email: gad.abikhzer@mcgill.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4R3E8
- Recruiting
- Jewish General Hospital
-
Contact:
- Gad Abikhzer, MDCM
- Email: gad.abikhzer@mcgill.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with suspected GCA
Description
Inclusion Criteria:
- Age ≥ 50 years, capable and willing to provide informed consent and can tolerate PET/CT.
- ESR ≥ 50 mm/h and/or CRP ≥ 10mg/L within 1 week of PET/CT referral.
- New suspected giant cell arteritis according to at least one of the following criteria:
Cranial GCA symptoms (new-onset localized headache, scalp or temporal artery tenderness, ischemia-related vision loss, masseter pain on prolonged mastication) PMR symptoms: shoulder and/or hip girdle pain associated with inflammatory stiffness.
Suspected large-vessel vasculitis based on angiography, MRA, or CTA.
Exclusion Criteria:
- Initiation of corticosteroid or immunosuppressive therapy >4 days before PET/CT.
- Prior TAB or treated GCA with suspected relapse.
- Non-fasting or hyperglycemia (>11.1 mmol/L) resulting in altered FDG biodistribution.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic Performance
Time Frame: 2 years
|
of Digital PET/CT and DUS for the diagnosis of GCA
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 10, 2022
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
August 3, 2021
First Submitted That Met QC Criteria
August 3, 2021
First Posted (Actual)
August 11, 2021
Study Record Updates
Last Update Posted (Estimated)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Skin Diseases, Vascular
- Vasculitis, Central Nervous System
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- Arteritis
- Vasculitis
Other Study ID Numbers
- MP-05-2021-2846
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
University Hospital, BrestRecruiting
-
Nantes University HospitalINSERM UMRS-1064CompletedANCA-associated VasculitisFrance
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
Clinical Trials on FDG PET/CT
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Region VästerbottenUmeå UniversityRecruitingCervix Cancer | Endometrial Cancer | Epithelial Ovarian CancerSweden
-
Institute of Oncology LjubljanaUniversity of LjubljanaUnknownCorrelation of iRADIOMICS and irRC With SurvivalSlovenia
-
Centre Hospitalier Universitaire Saint PierreCompletedExtrapulmonary Tuberculosis in HIV Patients
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
University of ZurichWithdrawnAdenocarcinoma | Stomach Cancer | Cancer of Esophagogastric JunctionSwitzerland
-
Rabin Medical CenterUnknown